TRECYLVIS Trademark

Trademark Overview

On Tuesday, April 27, 2021, a trademark application was filed for TRECYLVIS with the United States Patent and Trademark Office. The USPTO has given the TRECYLVIS trademark a serial number of 90674523. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, April 4, 2025. This trademark is owned by Pfizer Inc.. The TRECYLVIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
trecylvis

General Information

Serial Number90674523
Word MarkTRECYLVIS
Filing DateTuesday, April 27, 2021
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, April 4, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 11, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, April 4, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Friday, April 30, 2021NEW APPLICATION ENTERED
Monday, August 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 2, 2021ASSIGNED TO EXAMINER
Thursday, December 2, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 22, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 11, 2022PUBLISHED FOR OPPOSITION
Tuesday, January 11, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 8, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 3, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, August 3, 2022SOU EXTENSION 1 FILED
Wednesday, August 3, 2022SOU EXTENSION 1 GRANTED
Thursday, January 26, 2023SOU TEAS EXTENSION RECEIVED
Friday, August 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 26, 2023SOU EXTENSION 2 FILED
Thursday, January 26, 2023SOU EXTENSION 2 GRANTED
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Saturday, January 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 28, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 28, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 28, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023SOU EXTENSION 3 FILED
Wednesday, August 2, 2023SOU EXTENSION 3 GRANTED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 23, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 23, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 23, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 24, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 24, 2024SOU EXTENSION 4 FILED
Wednesday, January 24, 2024SOU EXTENSION 4 GRANTED
Friday, January 26, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 6, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 6, 2024SOU EXTENSION 5 GRANTED
Tuesday, August 6, 2024SOU EXTENSION 5 FILED
Thursday, April 3, 2025TEAS EXPRESS ABANDONMENT RECEIVED
Friday, April 4, 2025ABANDONMENT - AFTER PUBLICATION
Friday, April 4, 2025ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION

Related Keywords

trecylvis preparations disorders pharmaceutical treatment hypertension pain stroke cancer growth bone